BioWorld

Dec. 11, 2006

View Archived Issues

GSK Acquiring Young Antibody Firm Domantis For $454M Cash

In the latest example of big pharma turning to biotech to beef up its research and development pipelines, GlaxoSmithKline plc agreed to acquire Domantis Ltd. for £230 million (US$454 million) in cash. (BioWorld Today) Read More

Arena Pharmaceuticals Gets $159M For Stoked Pipeline

Read More

Double Trouble: Malaria, HIV Infection Feed Each Other

Read More

Theravance Submits NDA For Antibiotic Telavancin

Read More

Senate Finally OKs Von Eschenbach As FDA Head

Read More

Other News To Note

Read More

Clinic Roundup

Read More